|
2025
|
Invention
|
Combination therapies.
The present invention relates to combination therapies for treating KRas ... |
|
|
Invention
|
Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer.
Disclosed are compo... |
|
2024
|
Invention
|
Combination therapies using prmt5 inhibitors for the treatment of cancer.
This disclosure relate... |
|
|
Invention
|
Crystalline forms of mrtx0902. Rdd]pyridazin-1-yl)amino)ethyl)benzonitrile), pharmaceutical compo... |
|
|
Invention
|
Crystalline forms of fumarate salt of mrtx0902. The present invention relates to fumarate crystal... |
|
|
Invention
|
Mrtx1133 pharmaceutical compositions.
Solid pharmaceutical compositions of MRTX1133 (4-(4-((1R,5... |
|
|
Invention
|
Mrtx1133 pharmaceutical compositions. Solid pharmaceutical compositions of MRTX1133 (4-(4-((1R,5S... |
|
|
G/S
|
Pharmaceutical preparations; pharmaceutical preparations; pharmaceutical products; pharmaceutical... |
|
|
Invention
|
Stable 4-(aminomethyl)-6-(phenylpyrazolyl)phthalazinone compositions and processes for preparatio... |
|
|
Invention
|
Methods and compositions for treating malignant peripheral nerve sheath tumors. This disclosure r... |
|
|
Invention
|
Adagrasib solid pharmaceutical compositions.
Pharmaceutical compositions in solid form comprisin... |
|
|
Invention
|
Crystalline forms of a kras g12c inhibitor. The present invention relates to crystalline forms of... |
|
|
Invention
|
Processes and intermediates for synthesis of mrtx1133. The present invention relates to new synth... |
|
|
Invention
|
Crystalline forms of salts of adagrasib. The present invention relates to crystalline forms of sa... |
|
|
Invention
|
Kras g12s and g12c inhibitors. The present invention relates to compounds that inhibit KRas G12S ... |
|
|
Invention
|
Substituted quinoxalines.
Disclosed herein are substituted quinoxalines, methods for their prepa... |
|
|
Invention
|
Substituted quinoxalines. Disclosed herein are substituted quinoxalines, methods for their prepar... |
|
|
Invention
|
Kras g12d inhibitors.
The present invention relates to compounds that inhibit KRas G12D. In part... |
|
|
Invention
|
Crystalline forms of 2-(4-(4-(aminomethyl)-l-oxo-l,2- dihydrophthalazin-6-yl)-l-methyl-lh-pyrazol... |
|
|
Invention
|
Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2- dihydrophthalazin-6-yl)-1-methyl-1h- pyrazo... |
|
|
Invention
|
Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1h-pyrazol-... |
|
|
Invention
|
Substituted tricyclic compounds. Disclosed herein are substituted tricyclic compounds, including ... |
|
|
Invention
|
Processes and intermediates for synthesis of adagrasib. The present invention relates to new synt... |
|
|
Invention
|
Substituted spirocyclic-pyrroloquinazolinones and spirocyclic-piperidinoquinazolinones. Disclosed... |
|
2023
|
Invention
|
Processes and intermediates for synthesis of mrtx0902. The present invention relates to new synth... |
|
|
Invention
|
Combination therapies. The present invention relates to combination therapies for treating KRas G... |
|
|
Invention
|
Combination therapies using prmt5 inhibitors and bcl-2 family inhibitors for the treatment of can... |
|
|
Invention
|
Combination therapies using prmt5 inhibitors and bcl-2 family inhibitors for the treatment of cancer |
|
|
Invention
|
Kras g12c inhibitors.
The present invention relates to compounds that inhibit KRas G12C. In part... |
|
|
Invention
|
Combination therapies comprising a sos1 inhibitor and a mek inhibitor.
The present invention rel... |
|
|
Invention
|
Combination therapies comprising a sos1 inhibitor and an egfr inhibitor.
The present invention r... |
|
|
G/S
|
Pharmaceuticals; pharmaceutical preparations; pharmaceutical products; pharmaceutical preparation... |
|
2022
|
G/S
|
Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in o... |
|
|
Invention
|
Methods for separation of enantiomers.
The present invention relates to methods for separating e... |
|
|
Invention
|
Combination therapies using prmt5 inhibitors for the treatment of cancer.
Disclosed herein are m... |
|
|
Invention
|
Combinations of kras g12d inhibitors with irinotecan and related methods of treatment.
The prese... |
|
|
Invention
|
Combination therapies of kras g12d inhibitors with sos1 inhibitors.
The present invention relate... |
|
|
Invention
|
Combination therapies of kras g12d inhibitors with shp-2 inhibitors.
The present invention relat... |
|
|
Invention
|
Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment.
The... |
|
|
Invention
|
Combination therapies of kras g12d inhibitors with pan erbb family inhibitors.
The present inven... |
|
|
Invention
|
Processes and intermediates for synthesis of adagrasib.
The present invention relates to improve... |
|
|
G/S
|
pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in o... |
|
|
G/S
|
research and development of pharmaceuticals in the field of oncology; providing information in th... |
|
|
G/S
|
Downloadable computer software for use in customer relationship management (CRM); Downloadable en... |
|
|
Invention
|
Aminopyridine-based mta-cooperative prmt5 inhibitors.
The present invention relates to compounds... |
|
|
Invention
|
Sos1 inhibitors.
The present invention relates to compounds that inhibit Son of sevenless homolo... |
|
|
G/S
|
Medicinal preparations for use in oncology; pharmaceutical preparations for human use, namely, im... |
|
|
Invention
|
Kras g12c inhibitors.
The present invention relates to compounds that inhibit KRas G12C; in part... |
|
|
Invention
|
Mta-cooperative prmt5 inhibitors.
Disclosed are compounds of Formula IIA, IA-1, IIB, IIB-1, IIC ... |
|
|
G/S
|
Pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparati... |
|
|
G/S
|
Providing personal support services for families of patients with life threatening disorders, nam... |
|
2021
|
G/S
|
pharmaceutical preparations for the prevention and/or treatment of cancer; pharmaceutical prepara... |
|
|
G/S
|
Pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparatio... |
